Decitabine in the treatment of acute myeloid leukemia in elderly patients

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 53-61

  Malik, Priya ^a   Cashen, Amanda F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Decitabine; Elderly

Indexed keywords

EID: 84893532427     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S40600     Document Type: Review

References (56)

1. National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/amyl.html. Accessed June 16, 2013.
2. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224-2228.
3. Grimwade D, Walker H, Harrison G, etal. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5): 1312-1320.
4. Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica. 2005;90(11):1502-1510.
5. Schneider F, Hoster E, Schneider S, etal. Age-dependent frequencies of NPM1mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol. 2012;91(1):9-18.
6. Leith CP, Kopecky KJ, Godwin J, etal. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323-3329.
7. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8-13.
8. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483-5495.
9. Silverman LR, Demakos EP, Peterson BL, etal. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, etal. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
11. Kantarjian H, Issa JP, Rosenfeld CS, etal. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
12. Löwenberg B, Ossenkoppele GJ, van Putten W, etal. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
13. Tilly H, Castaigne S, Bordessoule D, etal. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-279.
14. Kantarjian H, O'Brien S, Cortes J, etal. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-1098.
15. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12): 1916-1924.
16. Rowe JM, Neuberg D, Friedenberg W, etal. A phase 3study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485.
17. Estey E, de Lima M, Tibes R, etal. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395-1400.
18. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Inter Med. 2002;162(14):1597-1603.
19. Burnett AK, Milligan D, Prentice AG, etal. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-1124.
20. Castaigne S, Pautas C, Terre C, etal. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3study. Lancet. 2012;379(9825):1508-1516.
21. Petersdorf SH, Kopecky KJ, Slovak M, etal. A phase 3study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology version 2.2013: acute myeloid leukemia. Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed June 16, 2013.
23. Tran H, Yang D. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. Ann Pharmacother. 2012;46(1): 89-96.
24. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;72(8):1111-1136.
25. Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res. 1984;8(6):1043-1049.
26. Petti MC, Mandelli F, Zagonel V, etal. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 1993;7 Suppl 1:36-41.
27. Willemze R, Suciu S, Archimbaud E, etal. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 1997;11 Suppl 1:S24-S27.
28. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85-93.
29. Momparler RL. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol. 2005;42(3 Suppl 2):S9-S16.
30. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncology. 2005;2 Suppl 1:S4-S11.
31. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-2054.
32. Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324-1341.
33. Schoofs T, Müller-Tidow C. DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev. 2011;37 Suppl 1:S13-S18.
34. Agrawal S, Hofmann WK, Tidow N, etal. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007;109(9):3895-3905.
35. Lübbert M, Suciu S, Baila L, etal. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996.
36. Issa JP, Garcia-Manero G, Giles FJ, etal. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635-1640.
37. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, etal. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-3279.
38. Blum W, Klisovic RB, Hackanson B, etal. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891.
39. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561.
40. Kantarjian H, Oki Y, Garcia-Manero G, etal. Results of a randomized study of 3schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57.
41. Steensma DP, Baer MR, Slack JL, etal. Multicenter study of decitabine administered daily for 5days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842-3848.
42. Blum W, Garzon R, Klisovic RB, etal. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16): 7473-7478.
43. Lübbert M, Rüter BH, Claus R, etal. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393-401.
44. Kantarjian HM, Thomas XG, Dmoszynska A, etal. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
45. Sekeres MA, Steensma DP. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol. 2012;30(33): 4061-4063.
46. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, etal. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
47. Kantarjian H, Wilson W, Ravandi F, Estey E. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol. 2013;31(14):1795-1796.
48. Ravandi F, Issa JP, Garcia-Manero G, etal. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115(24):5746-5751.
49. Furlan I, Batz C, Flotho C, etal. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113(12):2867-2868.
50. Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood. 2007;110(3):1080-1082; author reply 1083.
51. Lübbert M, Bertz H, Rüter B, etal. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44(9): 585-588.
52. Lübbert M, Bertz H, Müller MJ, Finke J. When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. J Clin Oncol. 2013;31(6):822-823.
53. ClinicalTrials. gov [website on the Internet]. Available from: http://www.clinicaltrials.gov. Accessed June 16, 2013.
54. Kalac M, Scotto L, Marchi E, etal. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20): 5506-5516.
55. Metzeler KH, Walker A, Geyer S, etal. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5):1106-1107.
56. Lavelle D, Vaitkus K, Ling Y, etal. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 2012;119(5):1240-1247.